mirikizumab mirikizumab mirikizumab (inn; trade name omvoh; development code ly3074828) is a human monoclonal antibody designed for the treatment of immune-mediated diseases psoriasis and ulcerative colitis. mirikizumabmonoclonal antibodytype?sourcehumanized (from mouse)targetinterleukin 23aclinical datatrade namesomvohother namesly3074828atc codenonelegal statuslegal status rx in japan identifierscas number1884201-71-1chemspidernoneuniiz7hvy03phpkeggd11123chemical and physical dataformulac6380h9842n1686o2004s48molar mass143767.59 g·mol−1 this drug was developed by eli lilly and co. in 2023, mirikizumab was approved as a first-in-class treatment for adults with moderately to severely active ulcerative colitis in japan; however, approval in the united states has not been granted due to manufacturing issues.